34-acre campus supports 200,000 square feet of GMP manufacturing, with long-term expansion capacity exceeding one million square feet
SpectronRx, a global radiopharmaceutical CDMO, CMO and isotope producer, today announced $85 million in financing from OrbiMed to expand its medical isotope production and manufacturing capacity.
The
investment will further strengthen SpectronRx’s fully integrated platform,
which brings together isotope production, drug development, scale-up and GMP
manufacturing within a single, unified infrastructure. This end-to-end model is
designed to support radiopharmaceutical programs from early development through
commercialization, forming one of the industry’s most comprehensive
radiopharmaceutical ecosystems.
As
part of its ongoing expansion, the company will continue scaling production of
critical medical isotopes used in diagnostic imaging and radioligand therapies.
SpectronRx’s portfolio of high-purity isotopes includes Actinium-225,
Copper-64, Zirconium-89, Iodine-124, Indium-111, Radium-226, Fluorine-18,
Lutetium-177, Lead-212, Thorium-232, Thorium-228, Iodine-123, Iodine-131,
Technetium-99, Yttrium-90, Copper-67, Copper-61, Molybdenum-99, Rhenium-186,
Gallium-68, Germanium-68 and more. The funds will support continued investment in infrastructure to
scale production capacity, enhance CDMO and CMO capabilities, and secure a
reliable, commercial-ready isotope supply.
The
announcement follows the company’s recent acquisition of an additional 14 acres
and the construction of a new 150,000-square-foot production facility. The
Grissom Aeroplex campus now spans 34 acres and supports approximately 200,000 square
feet of GMP-aligned manufacturing space, purpose-built to support both isotope
production and contract manufacturing operations at scale. Company-wide,
SpectronRx now operates more than 400,000 square feet of radiopharmaceutical
production space across its global network.
“Radiopharmaceutical
innovation is advancing rapidly, but isotope supply and manufacturing capacity
remain critical constraints,” said John Zehner, CEO of SpectronRx. “This
investment enables us to expand production at scale while strengthening our
CDMO and CMO capabilities, supporting our partners from early development
through global commercialization.”
Designed
for high-throughput production of radioligand therapies (RLT) and diagnostic
doses, the Grissom Aeroplex campus currently supports more than 300,000 patient
doses annually. Its long-term master plan provides the flexibility to expand
beyond one million square feet of production space, positioning SpectronRx to
meet growing global demand for decades to come.
“Reliable
access to high-quality medical isotopes and integrated manufacturing services
is essential to advancing the next generation of precision diagnostics and
therapies,” said Lars Enstrom, Managing Director at OrbiMed. “SpectronRx’s
combined CDMO, CMO and isotope production platform, along with its expanding
infrastructure, positions the company to play a critical role in enabling the
continued growth of the radiopharmaceutical sector.”
SpectronRx
currently supplies radiopharmaceuticals and isotopes across the United States
and internationally, with partners in South America, Europe, Japan, Korea,
India, China and Australia. The Grissom Aeroplex campus further strengthens
this global reach, supported by an adjacent 24/7 general aviation airport,
proximity to major international cargo hubs and access to more than 60% of the
U.S. population within a 12-hour drive. Additionally, all GMP operations comply
with 21 CFR Part 211, 21 CFR Part 212 and EU Annex 1 requirements, supporting
both sterile and non-sterile radiopharmaceutical manufacturing for global
markets.
In addition to its Grissom Aeroplex campus, SpectronRx’s
global network of facilities also includes:
Built
for scalability, redundancy and uninterrupted global supply, SpectronRx’s
network is designed around a partner-focused model, with facilities engineered
to protect customer intellectual property and ensure business continuity.
“Our
model is intentionally built to support our partners, not compete with them,”
said Anwer Rizvi, President of SpectronRx. “By integrating isotope production
with CDMO and CMO services within a single platform, we reduce complexity,
accelerate timelines, and improve reliability across the entire lifecycle of a
radiopharmaceutical program.”
SpectronRx’s
integrated approach provides a proven pathway from concept to clinic, and from
clinical development to global commercial launch.
To
learn more, visit SpectronRx.com.